Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in hemophilia patients with high-titer inhibitors
Geir E Tjønnfjord, Pål Andre HolmeMedical Department, Division of Hematology, Rikshospitalet- Radiumhospitalet Medical Center, Oslo, NorwayAbstract: The development of high-titer inhibitors to FVIII and less often to other coagulation factors are the most serious complication of...
Main Authors: | Geir E Tjønnfjord, Pål Andre Holme |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2007-09-01
|
Series: | Vascular Health and Risk Management |
Online Access: | https://www.dovepress.com/factor-eight-inhibitor-bypass-activity-feiba-in-the-management-of-blee-peer-reviewed-article-VHRM |
Similar Items
-
Real-world data in patients with congenital hemophilia and inhibitors: final data from the FEIBA Global Outcome (FEIBA GO) study
by: Carmen Escuriola Ettingshausen, et al.
Published: (2023-07-01) -
Fixed-Dose Factor Eight Inhibitor Bypassing Activity (FEIBA) in the Management of Warfarin-Associated Coagulopathies
by: Francisco Ibarra, et al.
Published: (2022-04-01) -
Combination of novoseven and feiba in hemophiliac patients with inhibitors
by: Malkan Umit Yavuz, et al.
Published: (2018-12-01) -
Successful bleeding control of refractory hemothorax in two hemophilia A patients with high-titer inhibitors
by: Ting-Chih Lin, et al.
Published: (2020-06-01) -
Challenges and successes in the treatment of hemophilia: the story of a patient with severe hemophilia A and high-titer inhibitors
by: Saba HI, et al.
Published: (2012-05-01)